Biotech Values

[DewDiligence]

Good_news_and_bad_news—GSK’s RSV vaccine protects_older_adults_for_two_seasons:

https://www.businesswire.com/news/home/20230620554754/en

This is good news for society, but probably bad news for GSK, PFE, and MRNA (the main players in the adult RSV-vaccine market). From the above PR:

The [GSK] trial also evaluated efficacy following an annual revaccination schedule as a confirmatory secondary endpoint. Cumulative efficacy over two seasons in participants who received a second dose of the vaccine was 67.1% [almost identical to the cumulative two-season efficacy of the single-dose regimen]…, suggesting revaccination after 12 months does not appear to confer additional benefit for the overall population.

[GSK’s] clinical development program will continue to evaluate longer-term follow up and the optimal timing for potential revaccination.

So, annual adult vaccinations for RSV will probably not become the SoC, which presumably means lower annual revenue for these medicines than some investors previously thought.